• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vaxess Technologies raises $2M for its silk-based vaccine delivery through the skin

March 26, 2021 By Sean Whooley

Vaxess Technologies today filed an SEC Form D to confirm the sale of $2 million in debt, options, warrants or other rights to buy securities.

According to the filing, three investors contributed to the new notice offering, which made its first sale on Monday, March 22, 2021, before reaching its total offering amount of $2 million today.

Cambridge, Mass.-based Vaxess did not make the offering in connection with a business combination transaction, such as a merger, acquisition or exchange offer. The company had not intended for it to last more than a year, as it took just four days.

The company did not list an intended use of proceeds. Vaxess develops a pipeline of proprietary MIMIX therapies, including ones for infectious diseases like COVID-19 and flu.

MIMIX, through just minutes of wear-time, enables the sustained release of treatments in the skin over minutes to as long as months. The company’s biomaterials technologies are based on silk, with the material’s unique properties offering a strong building block for biomaterial construction.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Vaxess Technologies

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS